# Convalescent Plasma to Limit SARS-CoV-2 Associated Complications

> **NCT04373460** · PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 1225 (actual)

## Conditions studied

- SARS-CoV 2

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 convalescent plasma
- **BIOLOGICAL:** Plasma from a volunteer donor

## Key facts

- **NCT ID:** NCT04373460
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-03
- **Primary completion:** 2022-01-14
- **Final completion:** 2022-12-14
- **Target enrollment:** 1225 (ACTUAL)
- **Last updated:** 2023-06-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373460, "Convalescent Plasma to Limit SARS-CoV-2 Associated Complications". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04373460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*